Partner with us
We are driven to make an impact in patient lives – and we innovate across the entire continuum of care in ways no other company can.
Our approach to business development
We boldly pursue transformational licensing, acquisition, and collaboration opportunities that accelerate breakthrough innovation to prevent, treat and cure some of the world’s most challenging diseases, including those that have few or no effective treatments today. Our approach is rooted in trust and transparency, leading to long-term partnering success with a proven, positive track record of deal performance. These investments and collaborations continue to strengthen our pipeline with new, investigational assets like our targeted oral peptide, antibody drug conjugates (ADCs), next-generation chimeric antigen receptor (CAR) T-cell therapies, and with breakthrough innovations that have reached patients, including RYBREVANT, DARZALEX and CARVYKTI.
Interested in collaborating? Contact us with your idea.
Partnering areas of focus
Through strategic partnerships and acquisitions, we deliver medicines for some of the world’s most challenging diseases, including those with few or no effective treatments today. We’re focused in areas where patient need is high, market opportunity is significant, and our expertise is deep.
We are driven by our bold vision to eliminate cancer. With more than 30 years of delivering transformational innovations in oncology, our commitment to pioneer new frontiers and therapies has never been stronger.
• Myeloid leukemia
• B-cell lymphoma
• Multiple myeloma
• Bladder cancer
• Lung cancer
• Prostate cancer
• Immuno-oncology
• Myeloid leukemia
• B-cell lymphoma
• Multiple myeloma
• Bladder cancer
• Lung cancer
• Prostate cancer
• Immuno-oncology
Inspired by the promise of helping patients reclaim their lives, we are delivering transformational, accessible therapies and regimens to patients with autoimmune diseases.
• Rheumatology
• Immunodermatology
• Gastroenterology
• Maternal fetal disease
• Rare autoantibody diseases
• Rheumatology
• Immunodermatology
• Gastroenterology
• Maternal fetal disease
• Rare autoantibody diseases
We are reducing the disability and devastation caused by serious neuropsychiatric, neurodegenerative, and autoantibody-driven diseases. For more than 60 years, our goal has been to discover major breakthroughs and deliver solutions that improve outcomes in areas of critical unmet need.
• Alzheimer’s disease
• Parkinson’s disease
• Depression
• Bipolar disorder
• Schizophrenia
• Alzheimer’s disease
• Parkinson’s disease
• Depression
• Bipolar disorder
• Schizophrenia
We have an unrelenting vision to ease the tremendous global burden of cardiovascular disease and pulmonary hypertension. We are advancing therapies that improve lives, change the treatment paradigm, enable access, and offer hope to patients living with these diseases.
• Atrial fibrillation
• Stroke
• Cardiomyopathy
• Thrombosis
• Heart failure
• Pulmonary hypertension
• Pulmonary fibrosis
• Atrial fibrillation
• Stroke
• Cardiomyopathy
• Thrombosis
• Heart failure
• Pulmonary hypertension
• Pulmonary fibrosis
We aim to achieve extraordinary discoveries, including gene therapy innovations, to restore and preserve vision for those living with retinal diseases such as Geographic Atrophy (GA).
We are taking a holistic approach to unlocking the promises of Interventional Oncology and enabling transformational regimens including intratumorally administered agents.
• Intratumoral delivery
• Radiation/Drug combinations
• Therapeutic energy
• Intratumoral delivery
• Radiation/Drug combinations
• Therapeutic energy
From early discovery, non-clinical safety, clinical manufacturing and supply our team covers the entire drug discovery and development process, crossing all modalities and support of J&J focus areas.
• Small molecules
• Protein therapeutics
• mRNA and SiRNA therapeutics
• Drug delivery solutions
• Supply chain technologies
• Small molecules
• Protein therapeutics
• mRNA and SiRNA therapeutics
• Drug delivery solutions
• Supply chain technologies
We are reimagining the discovery and development of medicines that advance our mission of leading where medicine is going to transform health for humanity.
• Artificial intelligence and machine learning approaches for target and biomarker identification
• Molecular invention
• Chemistry, manufacturing and controls
• Clinical rail design and process enhancement
• Novel digital endpoints and diagnostics
• Artificial intelligence and machine learning approaches for target and biomarker identification
• Molecular invention
• Chemistry, manufacturing and controls
• Clinical rail design and process enhancement
• Novel digital endpoints and diagnostics
Work with us
Through purpose-driven collaboration, we can accomplish truly remarkable advances in human health.
Contact our Innovative Medicine business development team to discuss post proof-of-concept opportunities.
For pre proof-of-concept licensing opportunities or research collaborations, please visit the Johnson & Johnson Innovation team website
Contact our Innovative Medicine business development team to discuss post proof-of-concept opportunities.
For pre proof-of-concept licensing opportunities or research collaborations, please visit the Johnson & Johnson Innovation team website